SK bioscience Co.,Ltd. (KRX:302440)

South Korea flag South Korea · Delayed Price · Currency is KRW
40,200
+1,400 (3.61%)
At close: May 8, 2025, 3:30 PM KST
-32.89%
Market Cap 3.10T
Revenue (ttm) 267.55B
Net Income (ttm) -53.88B
Shares Out 78.37M
EPS (ttm) -698.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 238,413
Average Volume 87,554
Open 39,400
Previous Close 38,800
Day's Range 39,400 - 41,650
52-Week Range 35,800 - 61,900
Beta 1.18
RSI 52.21
Earnings Date Apr 28, 2025

About SK bioscience

SK bioscience Co.,Ltd. engages in the research and development, production, and distribution of vaccines and biopharmaceuticals in Korea and internationally. Its product portfolio includes Skycellflu, a cell cultured influenza surface antigen vaccine; Skycellflu 4-ga pre-filled syringe; pneumococcal vaccine for adult and infant; Skyzoster, a shingles virus vaccine; and Sky Baricella for the prevention of chickenpox infection in children. The company also engages in the development of oral rotavirus vaccine that has completed phase 2 clinical tr... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2018
Employees 984
Stock Exchange Korea Stock Exchange
Ticker Symbol 302440
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.